Research Tracker›Biomarker Atlas›Multiple Sclerosis›CXCL13

CXCL13 in Multiple Sclerosis

CXCL13 is a other marker with mixed findings in Multiple Sclerosis: studies comparing patients with postmortem MS cases with low levels of meningeal inflammation and GM demyelination report both increases and decreases. The cited literature links this alteration to high levels of meningeal inflammation and GM demyelination. The finding is drawn from Magliozzi et al. 2018; it describes group-level differences, not a threshold that classifies an individual.

↕ InconsistentOther

Summary

Direction in Multiple Sclerosis↕ Inconsistent — reported as both higher and lower across studies, with no consistent direction
CategoryOther
Compared againstpostmortem MS cases with low levels of meningeal inflammation and GM demyelination
Associated symptomshigh levels of meningeal inflammation and GM demyelination
SourceMagliozzi et al. 2018 — doi:10.1002/ana.25197
Condition atlasMultiple Sclerosis Biomarker Atlas

Related Other markers in Multiple Sclerosis

Full list: Multiple Sclerosis Biomarker Atlas.

Frequently asked questions

Is CXCL13 high or low in Multiple Sclerosis?

Mixed. Some studies report higher and others lower CXCL13 in Multiple Sclerosis compared with postmortem MS cases with low levels of meningeal inflammation and GM demyelination, so no single direction is established. Source: Magliozzi et al. 2018.

What symptoms is CXCL13 associated with in Multiple Sclerosis?

The cited literature associates this marker with high levels of meningeal inflammation and GM demyelination. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures CXCL13?

The atlas record does not list a standardised clinical test code (LOINC) for CXCL13, which usually means it was measured with research assays or study-specific protocols rather than a routine clinical panel. Check the cited source for the exact method.

Is one abnormal CXCL13 result diagnostic of Multiple Sclerosis?

No. No single biomarker is diagnostic of Multiple Sclerosis. CXCL13 findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). CXCL13 in Multiple Sclerosis: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 8, 2026, from https://research.opensourcemed.info/biomarkers/multiple-sclerosis/cxcl13.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-10-08 · Page generated from multiple-sclerosis.json · Browse: Multiple Sclerosis atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.